Insulet (Nasdaq:PODD) announced today that its board of directors appointed Ashley McEvoy as president and CEO, effective immediately. McEvoy, a longtime Johnson & Johnson MedTech executive, also joins the company’s board. She succeeds Jim Hollingshead in the corner office of the Acton, Massachusetts-based automated insulin delivery technology developer. Hollingshead agreed with Insulet’s board that his […]
Insulet
Doctors issue call to action to eliminate barriers to automated insulin delivery
Key opinion leaders issued a call to action to the diabetes community to recognize the importance of automated insulin delivery (AID). A number of doctors issued this call, published by Mary Ann Liebert’s Diabetes Technology & Therapeutics, to implement the advances made in the AID technology space. They say pivotal trials and real-world data support […]
Insulet launches Omnipod 5 in Canada
Insulet (Nasdaq:PODD) announced today that it commercially launched the Omnipod 5 automated insulin delivery (AID) system in Canada. The first tubeless, waterproof AID system is approved in Canada for people with type 1 diabetes ages two years and above. In Canada, it pairs with the Dexcom G6 and G7 continuous glucose monitor (CGM) systems to […]
The biggest diabetes tech news out of ATTD 2025
Last week, Amsterdam played host to this year’s edition of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). For the 18th edition of this event, some of the biggest names in diabetes technology put their latest innovations on display. Updates for insulin delivery and glucose monitoring technologies dominated the headlines as many […]
Insulet study shows improvements with Omnipod 5 transitioning from multiple daily injections
Insulet (Nasdaq:PODD) today announced new Omnipod 5 clinical data highlighting the transition from multiple daily injections (MDI). Investigators shared data from the RADIANT study at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Amsterdam. The randomized controlled trial evaluated the direct transition from MDI to automated insulin delivery (AID). Insulet […]
Insulet CTO Mark Field departs for new opportunities
Insulet (Nasdaq:PODD) announced today that SVP and Chief Technology Officer Mark Field is departing the company. Field left the automated insulin delivery technology developer to pursue other opportunities, effective March 14, according to an SEC filing. As the company searches for Field’s successor, it tapped Amit Guliani to hold the post of interim CTO, effective […]
Insulet expands Omnipod 5 to more countries, prices $450M offering
Insulet (Nasdaq:PODD) announced today that it made its Omnipod 5 automated insulin delivery system available in several new geographies. The company made Omnipod 5 available in Australia and has planned launches for Belgium, Canada and Switzerland in the near term. This follows the launch of Omnipod 5 in five new European countries at the start […]
Real-world data backs Insulet Omnipod 5 in children
A recently published study highlighted the strong performance of the Insulet (Nasdaq:PODD) Omnipod 5 in children and young people. Omnipod 5, Insulet’s latest-generation automated insulin delivery (AID) system, is a small, discreet, tubeless, wearable patch pump. It features SmartAdjust technology that uses CGM readings to predict where glucose will be 60 minutes into the future. […]
Insulet sales increase 22% in 2024, Q4 performance beats Street
Insulet (Nasdaq:PODD) shares dipped after hours today on fourth-quarter results that came in ahead of the consensus forecast. Shares of PODD fell 2.7% to $280.66 apiece in post-market trading on Thursday, Feb. 21. By midday trading on Friday, Feb. 22, shares were down 2.4%, at 281.36. The Acton, Massachusetts–based automated insulin delivery technology maker reported […]
Insulet Omnipod 5 produces positive study outcomes in type 2 population
JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 diabetes. Omnipod 5, the company’s latest-generation automated insulin delivery (AID) system, became the first and only such system cleared for type 1 and type 2 diabetes last August. Insulet said at the time […]
